The distribution of the vaccine in Canada will be prioritized according to the populations identified by the National Advisory Committee on Immunizations. BioNTech will hold the regulatory approval in Canada, while Pfizer Canada will have commercialization rights.

Health Canada's decision is based on data filed through a rolling submission regulatory pathway and included data from phase II/III clinical trials which began in July 2020 and has enrolled approximately 44,000 people globally.

Pfizer Canada and BioNTech will supply the Canadian government a minimum of 20 million doses and up to 76 million doses of the vaccine through 2021.

Pfizer, BioNTech COVID-19 vaccine gets emergency approval in the U.K.
The Medicines and Healthcare Products Regulatory Agency in the U.K. has granted a temporary authorization for emergency use for BNT162b2, Pfizer and BioNTech's...

Pfizer, BioNTech submit CMA to EMA for COVID-19 vaccine
Pfizer and BioNTech submitted an application on November 30 for conditional marketing authorization (CMA) to the European Medicines Agency (EMA) for...

Pfizer, BioNTech to submit EUA request
Pfizer and BioNTech will submit a request on November 20 to the U.S. Food and Drug Administration for emergency use authorization (EUA) of their messenger...

Pfizer, BioNTech tout positive results for COVID-19 vaccine
Pfizer and BioNTech have released results from a phase III clinical trial evaluating their messenger RNA-based vaccine candidate, BNT162b2, demonstrating...

PerkinElmer to acquire Horizon Discovery for $383M
PerkinElmer has reached an agreement to acquire Horizon Discovery Group with an all-cash offer of approximately $383 million. The transaction is...